1,323 Intuitive Surgical, Inc. $ISRG Shares Sold by Wealth Enhancement Trust Services Inc.

Wealth Enhancement Trust Services Inc. lowered its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 13.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,458 shares of the medical equipment provider’s stock after selling 1,323 shares during the period. Wealth Enhancement Trust Services Inc.’s holdings in Intuitive Surgical were worth $3,439,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in ISRG. S.E.E.D. Planning Group LLC grew its stake in Intuitive Surgical by 17.1% in the third quarter. S.E.E.D. Planning Group LLC now owns 33,613 shares of the medical equipment provider’s stock valued at $13,668,000 after purchasing an additional 4,901 shares during the last quarter. North Point Portfolio Managers Corp OH purchased a new stake in shares of Intuitive Surgical during the third quarter valued at about $27,000. Strong Retirement Solutions LLC boosted its holdings in shares of Intuitive Surgical by 16.3% in the 3rd quarter. Strong Retirement Solutions LLC now owns 3,689 shares of the medical equipment provider’s stock valued at $1,500,000 after buying an additional 516 shares in the last quarter. Moody National Bank Trust Division grew its position in shares of Intuitive Surgical by 40.8% in the 3rd quarter. Moody National Bank Trust Division now owns 5,924 shares of the medical equipment provider’s stock worth $2,409,000 after buying an additional 1,716 shares during the last quarter. Finally, Private Capital Advisors Inc. bought a new position in shares of Intuitive Surgical during the 3rd quarter worth approximately $495,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Trading Up 2.4%

NASDAQ ISRG traded up $9.76 on Wednesday, hitting $414.52. 1,895,998 shares of the company’s stock traded hands, compared to its average volume of 2,423,132. The firm’s 50-day moving average price is $383.70 and its two-hundred day moving average price is $411.61. The firm has a market capitalization of $146.44 billion, a PE ratio of 47.48, a P/E/G ratio of 3.07 and a beta of 1.46. Intuitive Surgical, Inc. has a 1-year low of $328.57 and a 1-year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.48 by $0.32. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The firm had revenue of $2.89 billion for the quarter, compared to analyst estimates of $2.83 billion. During the same quarter in the prior year, the business earned $1.81 earnings per share. The business’s quarterly revenue was up 18.4% compared to the same quarter last year. On average, research analysts anticipate that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. KeyCorp restated an “overweight” rating on shares of Intuitive Surgical in a research note on Wednesday, August 12th. Royal Bank Of Canada reduced their price target on Intuitive Surgical from $650.00 to $600.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Barclays began coverage on Intuitive Surgical in a report on Tuesday. They set an “overweight” rating and a $485.00 price objective for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Intuitive Surgical in a research report on Friday, August 14th. Finally, UBS Group initiated coverage on Intuitive Surgical in a research note on Tuesday, July 28th. They set a “neutral” rating and a $500.00 target price on the stock. Twenty-two equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus target price of $502.53.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Barclays began coverage of Intuitive Surgical with an Overweight rating, adding a new bullish view on the shares. Barclays starts coverage of Intuitive Surgical stock at Overweight
• Positive Sentiment: Citi reportedly assigned ISRG a Buy rating, reinforcing the recent improvement in sell-side sentiment. Intuitive Surgical gets a Buy from Citi
• Positive Sentiment: Intuitive Surgical’s single-port robotic platform is gaining traction, with rising procedures, utilization and system placements. Expanding clinical indications and international adoption could turn the platform into a major billion-dollar franchise and provide an additional growth engine beyond the company’s established da Vinci systems. Can ISRG’s Single-Port Platform Become the Next Billion-Dollar Franchise?
• Positive Sentiment: Recent commentary argues that the stock’s valuation multiple has fallen while the underlying growth story remains intact. A recovery in system sales, procedure volumes and recurring instruments-and-accessories revenue could support a rebound after a weak trailing year. Intuitive Surgical: The Multiple Fell, The Story Didn’t
• Neutral Sentiment: An industry outlook highlighted Intuitive Surgical alongside Globus Medical and Thermo Fisher Scientific, but provided limited company-specific detail or a clear new catalyst. Zacks Industry Outlook
• Negative Sentiment: Jim Cramer expressed less enthusiasm for ISRG, citing the growing number of competitors—particularly Johnson & Johnson—as a threat to the company’s long-term positioning. This underscores the risk that competition could pressure growth or valuation. Intuitive Surgical and JNJ Give Jim Cramer More Than Valuation to Consider

Insider Buying and Selling at Intuitive Surgical

In related news, Director Gary S. Guthart sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $400.00, for a total transaction of $4,000,000.00. Following the sale, the director directly owned 1,245,679 shares of the company’s stock, valued at $498,271,600. This trade represents a 0.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy L. Ladd sold 400 shares of Intuitive Surgical stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $379.00, for a total value of $151,600.00. Following the transaction, the director owned 251 shares of the company’s stock, valued at approximately $95,129. This represents a 61.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 12,370 shares of company stock worth $4,891,989. Insiders own 0.60% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops and commercializes robotic-assisted systems and related technologies designed to support minimally invasive medical procedures. The company’s products are intended to help surgeons perform operations through small incisions while providing enhanced visualization, precision, and control.

Its principal product is the da Vinci Surgical System, a platform used across a range of specialties, including general surgery, urology, gynecology, thoracic surgery, and cardiac procedures.